BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu C. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: Resolved and unresolved issues: Treatment of dual hepatitis C and B. J Gastroenterol Hepatol 2014;29:26-30. [DOI: 10.1111/jgh.12421] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Said ZNA, El-Sayed MH. Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings. World J Hepatol 2022; 14(7): 1333-1343 [DOI: 10.4254/wjh.v14.i7.1333] [Reference Citation Analysis]
2 Shahriar S, Araf Y, Ahmad R, Kattel P, Sah GS, Rahaman TI, Sadiea RZ, Sultana S, Islam MS, Zheng C, Hossain MG. Insights Into the Coinfections of Human Immunodeficiency Virus-Hepatitis B Virus, Human Immunodeficiency Virus-Hepatitis C Virus, and Hepatitis B Virus-Hepatitis C Virus: Prevalence, Risk Factors, Pathogenesis, Diagnosis, and Treatment. Front Microbiol 2021;12:780887. [PMID: 35222296 DOI: 10.3389/fmicb.2021.780887] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
3 El-Khayat H, Yakoot M, El-Shabrawi M, Fouad Y, Attia D, Kamal EM. Treatment of Chronic Hepatitis C in Adolescent Patients With Positive HBsAg or With Occult Hepatitis B: Is the Risk of Hepatitis B Reactivation Significant? Pediatr Infect Dis J 2021;40:11-5. [PMID: 32925546 DOI: 10.1097/INF.0000000000002894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Owusu DO, Phillips R, Owusu M, Sarfo FS, Frempong M. Increased levels of circulating IL-10 in persons recovered from hepatitis C virus (HCV) infection compared with persons with active HCV infection. BMC Res Notes 2020;13:472. [PMID: 33028385 DOI: 10.1186/s13104-020-05313-w] [Reference Citation Analysis]
5 Liu Y, Zou X, Chen W, Gong C, Ling L. Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study. Int J Environ Res Public Health 2019;16:E4436. [PMID: 31726750 DOI: 10.3390/ijerph16224436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Ning Q, Wu T, Su H, Ma K, Qi J, Ni M, Wu D. Antiviral Therapy for AECHB and Severe Hepatitis B (Liver Failure). Acute Exacerbation of Chronic Hepatitis B 2019. [DOI: 10.1007/978-94-024-1603-9_5] [Reference Citation Analysis]
7 Huang H, Tang H, Deng H, Shen J, Zhou Q, Xie W, Wu J, Chen J. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients. Transpl Infect Dis 2019;21:e13018. [PMID: 30369001 DOI: 10.1111/tid.13018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Chong LW, Hsu CC, Lee CY, Chou RH, Lin CL, Chang KH, Hsu YC. Association of viral hepatitis and bipolar disorder: a nationwide population-based study. J Transl Med 2018;16:173. [PMID: 29929549 DOI: 10.1186/s12967-018-1542-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Paniagua-garcía M, López-hernández I, Fernández-cuenca F, Ríos-villegas MJ. Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV. Enfermedades infecciosas y microbiologia clinica (English ed ) 2017;35:681-682. [DOI: 10.1016/j.eimce.2017.11.009] [Reference Citation Analysis]
10 Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osinusi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology 2018;154:989-97. [PMID: 29174546 DOI: 10.1053/j.gastro.2017.11.011] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 16.4] [Reference Citation Analysis]
11 Paniagua-García M, López-Hernández I, Fernández-Cuenca F, Ríos-Villegas MJ. Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV. Enferm Infecc Microbiol Clin 2017;35:681-2. [PMID: 28366615 DOI: 10.1016/j.eimc.2017.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Yeh ML, Hsieh MY, Huang CI, Huang CF, Hsieh MH, Huang JF, Dai CY, Chuang WL, Yu ML. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection. J Gastroenterol Hepatol 2016;31:835-41. [PMID: 26478984 DOI: 10.1111/jgh.13203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zheng YB, Gu YR, Zhang M, Wang K, Huang ZL, Lin CS, Gao ZL. Health care workers in Pearl River Delta Area of China are not vaccinated adequately against hepatitis B: a retrospective cohort study. BMC Infect Dis 2015;15:542. [PMID: 26590815 DOI: 10.1186/s12879-015-1278-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
14 Toussaint-Miller KA, Andres J. Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. Ann Pharmacother 2015;49:1015-30. [PMID: 26139639 DOI: 10.1177/1060028015592015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
15 Wahle RC, Perez RDM, Emori CT, Uehara SNDO, Fucuta PDS, Rocha CM, Feldner ACDCA, Silva ISDSE, Carvalho-filho RJ, Silva AEB, Ferraz MLG. Does hepatitis B virus coinfection have any impact on treatment outcome in hepatitis C patients on hemodialysis? Annals of Hepatology 2015;14:317-324. [DOI: 10.1016/s1665-2681(19)31270-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Kimura H, Ohkawa K, Sakakibara M, Imanaka K, Matsunaga T, Miyazaki M, Miyagi T, Tatsumi T, Hiramatsu N, Takehara T, Katayama K. Sustained hepatitis C virus RNA clearance accompanied by elevation of hepatitis B virus DNA after short-term peginterferon-α, ribavirin and simeprevir therapy in a chronic hepatitis patient having dual infection with hepatitis B and C viruses. Acta hepatologica Japonica 2015;56:422-427. [DOI: 10.2957/kanzo.56.422] [Cited by in Crossref: 7] [Article Influence: 1.0] [Reference Citation Analysis]
17 Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;9:2051-67. [PMID: 24812506 DOI: 10.2147/IJN.S41822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]